We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights NVIDIA, Pfizer, Citigroup, Humana, and Canadian Natural Resources
Read MoreHide Full Article
For Immediate Release
Chicago, IL – October 11, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NVIDIA Corp. (NVDA - Free Report) , Pfizer Inc. (PFE - Free Report) , Citigroup Inc. (C - Free Report) , Humana Inc. (HUM - Free Report) , and Canadian Natural Resources Ltd. (CNQ - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for NVIDIA, Pfizer and Citigroup
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp., Pfizer Inc. and Citigroup Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
NVIDIA shares have underperformed the Zacks Semiconductor - General industry over the past year (-41.6% vs. -38.8%). The company’s near-term prospect looks gloomy due to weakening demand for its chips used in gaming and data center end markets. While the macroeconomic headwinds are impacting gaming chip demand, ongoing supply-chain issues are also hurting data center chip market.
The ongoing war between Russia and Ukraine is likely to continue negatively impact NVIDIA’s near-term revenues. Trade war between the US and China also remains a key concern.
However, solid uptake of artificial intelligence-based smart cockpit infotainment solutions is likely to aid NVIDIA growth. Additionally, collaboration with the likes of Mercedes-Benz and Audi is expected to further strengthen NVIDIA’s presence in the autonomous vehicles and other automotive electronics space.
Pfizer's shares have gained +0.6% over the past year against the Zacks Large Cap Pharmaceuticals industry’s gain of +5.6%. The company is strongly placed in the COVID vaccines/treatment market right now. Its COVID-19 vaccine together with the oral antiviral pill, Paxlovid is expected to generate a combined $54 billion in sales in 2022.
Pfizer boasts a sustainable pipeline with multiple late-stage programs that can drive growth. However, currency headwinds and pricing pressure are key top-line headwinds. Concerns remain about its long-term growth drivers beyond its COVID-related products due to competitive pressure.
Our estimates for Pfizer’s top line suggest a CAGR decline of around 30% over the next three years. Estimates are stable ahead of Q3 earnings. Pfizer has a decent record of earnings surprises in the recent quarters
Citigroup shares have underperformed the Zacks Banks - Major Regional industry over the past year (-41.2% vs. -29.1%). The company is burdened with numerous investigations and lawsuits, along with transformational expenses, which are limiting its bottom-line growth. The elimination of overdraft fees will impede fee income growth in the near term.
However, Citigroup’s earnings beat the Zacks Consensus Estimate in all of the trailing four quarters. It is progressing with its strategy to exit the global consumer banking business. With this, it will focus on institutional franchises, thereby improving long-term profitability.
The bank also intends to wind down its UK retail banking business, and expand personal banking and wealth management businesses in the region. Also, net interest income growth, decent liquidity and capital deployment plans are positives
Other noteworthy reports we are featuring today include Humana Inc., and Canadian Natural Resources Ltd.
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights NVIDIA, Pfizer, Citigroup, Humana, and Canadian Natural Resources
For Immediate Release
Chicago, IL – October 11, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NVIDIA Corp. (NVDA - Free Report) , Pfizer Inc. (PFE - Free Report) , Citigroup Inc. (C - Free Report) , Humana Inc. (HUM - Free Report) , and Canadian Natural Resources Ltd. (CNQ - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for NVIDIA, Pfizer and Citigroup
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp., Pfizer Inc. and Citigroup Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
NVIDIA shares have underperformed the Zacks Semiconductor - General industry over the past year (-41.6% vs. -38.8%). The company’s near-term prospect looks gloomy due to weakening demand for its chips used in gaming and data center end markets. While the macroeconomic headwinds are impacting gaming chip demand, ongoing supply-chain issues are also hurting data center chip market.
The ongoing war between Russia and Ukraine is likely to continue negatively impact NVIDIA’s near-term revenues. Trade war between the US and China also remains a key concern.
However, solid uptake of artificial intelligence-based smart cockpit infotainment solutions is likely to aid NVIDIA growth. Additionally, collaboration with the likes of Mercedes-Benz and Audi is expected to further strengthen NVIDIA’s presence in the autonomous vehicles and other automotive electronics space.
(You can read the full research report on NVIDIA here >>>)
Pfizer's shares have gained +0.6% over the past year against the Zacks Large Cap Pharmaceuticals industry’s gain of +5.6%. The company is strongly placed in the COVID vaccines/treatment market right now. Its COVID-19 vaccine together with the oral antiviral pill, Paxlovid is expected to generate a combined $54 billion in sales in 2022.
Pfizer boasts a sustainable pipeline with multiple late-stage programs that can drive growth. However, currency headwinds and pricing pressure are key top-line headwinds. Concerns remain about its long-term growth drivers beyond its COVID-related products due to competitive pressure.
Our estimates for Pfizer’s top line suggest a CAGR decline of around 30% over the next three years. Estimates are stable ahead of Q3 earnings. Pfizer has a decent record of earnings surprises in the recent quarters
(You can read the full research report on Pfizer here >>>)
Citigroup shares have underperformed the Zacks Banks - Major Regional industry over the past year (-41.2% vs. -29.1%). The company is burdened with numerous investigations and lawsuits, along with transformational expenses, which are limiting its bottom-line growth. The elimination of overdraft fees will impede fee income growth in the near term.
However, Citigroup’s earnings beat the Zacks Consensus Estimate in all of the trailing four quarters. It is progressing with its strategy to exit the global consumer banking business. With this, it will focus on institutional franchises, thereby improving long-term profitability.
The bank also intends to wind down its UK retail banking business, and expand personal banking and wealth management businesses in the region. Also, net interest income growth, decent liquidity and capital deployment plans are positives
(You can read the full research report on Citigroup here >>>)
Other noteworthy reports we are featuring today include Humana Inc., and Canadian Natural Resources Ltd.
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.